IGC Pharma Inc（IGC）資訊與事件IGCIGC Pharma Inc

IGC Pharma Strengthens Drug Development Capabilities as IGC-AD1 Expected to Report Results in Q4 2026

IGC Pharma announced that it is strengthening its regulatory, biostatistical, artificial intelligence-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the fourth quarter of 2026. CALMA has randomized 160 participants to date. IGC Pharma expects to close enrollment after up to additional participants, marking a key final enrollment milestone before patient follow-up, database lock, unblinding, and topline analysis. This final planned over-enrollment phase is intended to strengthen the dataset for end-of-treatment, secondary, and exploratory analyses.

IGC Pharma Evaluates Civil Remedies Following Verdict

IGC Pharma is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California. According to the United States Attorney's Office for the Central District of California, Andrew Left, founder of Citron Research, was found guilty of one count of engaging in a securities fraud scheme and 12 counts of securities fraud. The verdict follows a federal indictment that identified IGC, then known as India Globalization Capital, Inc., as one of the companies targeted in the alleged scheme. IGC is evaluating whether the public record supports potential claims to recover damages arising from the alleged short campaign and related conduct that affected the Company and its shareholders. The indictment alleged that, in October 2018, Left and a hedge fund worked together to execute a short campaign targeting IGC. The Company believes the public record raises serious questions regarding the conduct surrounding that campaign and its impact on IGC and its shareholders.IGC is reviewing the federal indictment, the jury verdict, and related SEC materials, and is evaluating potential civil remedies. The Company is also evaluating whether recoverable damages may include harm to market value, reputational and operational harm, and legal and regulatory costs incurred in connection with matters arising from the conduct described in the public record. Any decision to pursue claims will be made by the Board of Directors, based on the recommendation of counsel and in the best interests of the Company and its shareholders. The public record also describes financial incentives associated with the alleged short campaigns. The indictment alleged that trading related to short campaigns targeting IGC and another issuer generated more than $3.8M in profits for the hedge fund involved and more than $1.1M in profits for Left. In a separate settled administrative proceeding, the Securities and Exchange Commission order stated that Anson Advisors agreed to pay a short publisher a share of trading profits from trading around a bearish tweet concerning IGC. According to the SEC order, AIMF's short positions on the day of the IGC tweet generated approximately $500,000 in trading profits. Without admitting or denying the SEC's findings, Anson Funds Management LP and Anson Advisors Inc. agreed to pay combined civil monetary penalties of $2.25M.

IGC Pharma Launches Alzheimer's Data Harmonization Assistant

IGC Pharma announced the beta version of its proprietary Agentic Harmonization Assistant, an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer's and aging-related datasets. "Artificial intelligence is changing how medicines are discovered and developed, but AI models are only as powerful as the data they can learn from," said Ram Mukunda, CEO of IGC Pharma. "Our vision is for AHA to become a trusted infrastructure layer that helps pharmaceutical companies, academic institutions, government agencies, and healthcare data organizations convert fragmented biomedical datasets into interoperable, reusable, and AI-ready discovery assets." In internal testing using an Alzheimer's structured-data workflow involving 100 variables, AHA reduced harmonization time from 28 hours of manual processing to 2.5 hours, including human verification of results - a 90% reduction in workflow time for that representative test case.